ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
–
Operating margin
7.9%+0.0 pts over 5 years
Net margin
6.6%+1.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.0% | +7.8% | +10.8% | – | |
| Operating income | – | +26.1% | +10.9% | – | |
| Net income | +4201.0% | +33.6% | +16.5% | – | |
| EPS, diluted | – | +7.7% | 0.0% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 272.6% | 17.8% | 13.2% | |
| Return on assets | -10.9% | 6.7% | 6.8% | |
| Current ratio | 3.00 | 2.56 | 3.62 | |
| Debt to equity | – | – | – | |
| Interest coverage | -1.6× | 2.4× | -19.6× | |
| Inventory turnover | – | 3.4× | – | |
| Capex to revenue | 1.0% | 5.2% | 2.5% | |
| Diluted shares | 63M | 111M | 130M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Organogenesis generated $142.27M from operations and spent $139.14M on capital expenditure, dividends and share buybacks. 82% of that went back into the business.
Generated
$142.27M
Used
$139.14M
Capital expenditure$113.67M82%Dividends$00%Share buybacks$25.48M18%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.6%
×Asset turnover1.03×
×Equity multiplier1.95×
=Return on equity, FY202513.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.6% | 1.03× | 1.95× | 13.2% |
| FY2024 | 0.2% | 1.01× | 1.77× | 0.3% |
| FY2023 | 1.1% | 0.95× | 1.67× | 1.8% |
| FY2022 | 3.4% | 1.01× | 1.76× | 6.1% |
| FY2021 | 20.2% | 1.27× | 1.91× | 49.2% |
| FY2020 | 5.1% | 1.32× | 2.64× | 17.8% |
| FY2019 | -14.8% | 1.36× | 4.18× | -84.2% |
| FY2018 | -33.5% | 1.24× | 12.69× | -526.6% |
| FY2017 | -4.2% | 0.86× | -14.70× | 53.6% |
| FY2016 | -12.2% | 0.89× | -25.02× | 272.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$37.03M
- Cash generatingOperating cash flow above zero-$10.31M
- Return on assets improvedROA up on the prior year0.2% → 7.4%
- Earnings backed by cashOperating cash flow above net income-$10.31M vs $37.03M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.69 → 3.62
- No dilutionShare count did not rise132M → 130M
- Gross margin improvedGross margin up on the prior year75.99% → –
- More efficientAsset turnover rose1.05 → 1.13